Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Japan Doctors’ Lobby Braced for Tough Social Security Debate after Election
The Japan Medical Association (JMA) sees tough social security debates awaiting it after this summer’s Upper House election as the government puts off setting its cost curtailment target to garner support for the ruling Liberal Democratic Party, President Yoshitake Yokokura…
To read the full story
Related Article
- Japan Cabinet Adopts 2019 Honebuto Policy, No Big Change Made on Drug Pricing
June 24, 2019
- LDP Inscribes AI Utilization for Drug Development in Honebuto Paper
June 19, 2019
- Govt’s Draft Policy Blueprint Prods Continued Debates on Pricing Reform Proposals; Expanded HTA Use, Handling of PMP-Granted Comparators and More
June 12, 2019
ORGANIZATION
- Pharma Labor Group Logs Wage Hikes of around 4% at July-End
August 24, 2026
- Biotech Group Calls for Post-IPO Startups to Get AMED Support
August 19, 2026
- EFPIA Executive Hails Japan’s Honebuto as “Blueprint” for Europe
August 17, 2026
- New Chuikyo Pharmacist Rep Urges 2027 Revision to Stay within 4-Minister Deal
August 3, 2026
- Ectopic Fat Research Group Launches to Push Cross-Disciplinary Studies
July 31, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…